Equitable Trust Co. Acquires 84 Shares of ICU Medical, Inc. (NASDAQ:ICUI)

Equitable Trust Co. raised its holdings in shares of ICU Medical, Inc. (NASDAQ:ICUI) by 1.6% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 5,297 shares of the medical instruments supplier’s stock after purchasing an additional 84 shares during the period. Equitable Trust Co.’s holdings in ICU Medical were worth $822,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in ICUI. FMR LLC increased its stake in shares of ICU Medical by 2,676.6% during the third quarter. FMR LLC now owns 104,094 shares of the medical instruments supplier’s stock valued at $18,968,000 after purchasing an additional 100,345 shares in the last quarter. State Street Corp increased its position in shares of ICU Medical by 9.3% during the third quarter. State Street Corp now owns 907,607 shares of the medical instruments supplier’s stock valued at $165,384,000 after acquiring an additional 77,506 shares in the last quarter. Geode Capital Management LLC increased its position in shares of ICU Medical by 9.6% during the third quarter. Geode Capital Management LLC now owns 546,954 shares of the medical instruments supplier’s stock valued at $99,687,000 after acquiring an additional 48,106 shares in the last quarter. Charles Schwab Investment Management Inc. increased its position in shares of ICU Medical by 10.2% during the third quarter. Charles Schwab Investment Management Inc. now owns 301,107 shares of the medical instruments supplier’s stock valued at $54,868,000 after acquiring an additional 27,927 shares in the last quarter. Finally, Principal Financial Group Inc. increased its position in shares of ICU Medical by 24.6% during the third quarter. Principal Financial Group Inc. now owns 126,937 shares of the medical instruments supplier’s stock valued at $23,130,000 after acquiring an additional 25,031 shares in the last quarter. Institutional investors own 96.10% of the company’s stock.

Insiders Place Their Bets

In other news, CEO Vivek Jain sold 1,373 shares of the business’s stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $155.48, for a total transaction of $213,474.04. Following the completion of the sale, the chief executive officer now owns 104,593 shares of the company’s stock, valued at $16,262,119.64. The trade was a 1.30 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, COO Christian B. Voigtlander sold 1,962 shares of the business’s stock in a transaction on Monday, November 25th. The shares were sold at an average price of $169.08, for a total transaction of $331,734.96. The disclosure for this sale can be found here. In the last quarter, insiders sold 17,737 shares of company stock valued at $2,879,752. Company insiders own 6.70% of the company’s stock.

ICU Medical Trading Up 2.0 %

NASDAQ:ICUI opened at $159.78 on Tuesday. The company has a current ratio of 2.29, a quick ratio of 1.03 and a debt-to-equity ratio of 0.75. ICU Medical, Inc. has a 12 month low of $93.36 and a 12 month high of $196.26. The company has a market cap of $3.91 billion, a PE ratio of -34.96 and a beta of 0.63. The company has a 50 day simple moving average of $160.70 and a two-hundred day simple moving average of $164.00.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on ICUI. StockNews.com raised shares of ICU Medical from a “hold” rating to a “buy” rating in a research report on Wednesday, November 20th. KeyCorp raised their price target on shares of ICU Medical from $198.00 to $209.00 and gave the company an “overweight” rating in a research report on Wednesday, November 13th. Jefferies Financial Group raised shares of ICU Medical from a “hold” rating to a “buy” rating and set a $200.00 price target for the company in a research report on Wednesday, December 11th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of ICU Medical in a research report on Wednesday, November 13th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $199.67.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.